Key result
An antithrombin-supplemented anti-Xa heparin assay showed ≥80% agreement with nonsupplemented assays for classifying clinical adequacy of heparin levels, not improving clinical usefulness.
Why the study?
Does an antithrombin-supplemented anti-Xa assay improve clinical usefulness compared to nonsupplemented assays for monitoring unfractionated heparin in ICU patients?
Observational
Does an antithrombin-supplemented anti-Xa assay improve clinical usefulness compared to nonsupplemented assays for monitoring unfractionated heparin in ICU patients?
Effect estimate: ≥80% agreement
Antithrombin supplementation in anti-Xa heparin assays does not significantly improve clinical usefulness for monitoring intravenous unfractionated heparin in medical ICU patients.
Antithrombin-supplemented anti-Xa assays add no clinical value for heparin monitoring in ICU patients; hypothesis-generating and should not change practice.
The availability of automated anti-Xa heparin assays provides the opportunity to manage patient unfractionated heparin levels directly, rather than by the activated partial thromboplastin time. Because critically ill patients can acquire an antithrombin deficiency, we compared the performance of 3 anti-Xa heparin assays, 1 with and 2 without antithrombin supplementation, by analyzing in vitro aliquots of plasma with defined antithrombin levels and specimens from intensive care patients receiving intravenous heparin therapy. Heparin concentration recovery, in vitro, was dependent on the plasma antithrombin concentration for all 3 assays. The antithrombin-supplemented assay demonstrated improved heparin recovery in direct correlation to the heparin concentration in the plasma. The greatest effect of antithrombin supplementation occurred when the antithrombin level dropped below 40%, a level present in only 5% of the patient specimens. Analysis of patient specimens demonstrated significant correlation among the 3 assays. Classification of the clinical adequacy of patient heparin levels showed agreement of 80% or more between the antithrombin-supplemented and nonsupplemented assays. The antithrombin-supplemented assay did not significantly improve clinical usefulness.
No takes yet. Share an insight, caveat, or question.
Lehman et al. (2006) conducted an observational in Intensive care patients receiving intravenous unfractionated heparin therapy. Anti-Xa heparin assay with antithrombin supplementation vs. Anti-Xa heparin assays without antithrombin supplementation was evaluated on Classification of the clinical adequacy of patient heparin levels (≥80% agreement). An antithrombin-supplemented anti-Xa heparin assay showed ≥80% agreement with nonsupplemented assays for classifying clinical adequacy of heparin levels, not improving clinical usefulness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: